A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Name: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
Published: 2020
License: Public Domain

Hoffmann-La Roche · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

efficacy multiple-sclerosis

multiple sclerosis, primary progressive multiple sclerosis; higher dose of cd20 antibody ocrelizumab; efficacy, safety and pharmacokinetics, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Related documents